ClinicalTrials.govpublic full text
Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
all, childhood b-cell, acute lymphoid leukemia relapse, acute lymphocytic leukemia refractory, cd19 positive, refractory to standard treatment, relapse, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 800426
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.